Home / Posts Tagged "immunogenicity."

CEPI to provide funding of up to US$3.6 million to advance the development of Gennova Biopharmaceutical’s self-amplifying thermostable mRNA vaccine platform to develop vaccine candidates against Disease X. • Funding will support optimisation of the technology platform to enhance immunogenicity. 8 August 2023, OSLO Norway: The Coalition for Epidemic

READ MORE